Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2012

Conditions
Solid Tumors
Interventions
DRUG

Dasatinib

50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days

DRUG

Erlotinib

100 mg PO Daily for 28 Days Every 28 Days

DRUG

Lapatinib

1000 mg PO Daily for 28 Days Every 28 Days

DRUG

Lenalidomide

15 mg PO Daily for 28 Days Every 28 Days

DRUG

Sorafenib

400 mg PO Daily for 21 Days Every 28 Days

DRUG

Sunitinib

25 mg PO Daily for 21 Days Every 28 Days

DRUG

Valproic Acid

40 mg/kg PO Daily for 7 Days, then 7 Days Off

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00495872 - Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter